DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 07h30 HE
|
DMK Pharmaceuticals Corporation
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI®...
Compass Therapeutics to Participate in Upcoming Investor Events
07 nov. 2023 08h00 HE
|
Compass Therapeutics
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Global Cold Storage Construction Market to Reach Value of USD 35.48 Billion by 2032 | Emergen Research
06 nov. 2023 09h19 HE
|
Emergen Research
Vancouver, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The global cold storage construction market is projected to reach a market size of USD 35.48 Billion by 2032, and revenue growth is expected to be...
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
06 nov. 2023 07h30 HE
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant...
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
31 oct. 2023 08h23 HE
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
04 oct. 2023 07h30 HE
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the...
Fusion Inhibitors Market Revenue to Cross USD 7.2 billion by 2031, Exhibiting a 14.2% CAGR: TMR Report
04 oct. 2023 03h52 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
03 oct. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Syneos Health Appoints Colin Shannon as Chief Executive Officer
03 oct. 2023 08h00 HE
|
Syneos Health, Inc.
Syneos Health today appointed Collin Shannon as its new CEO. Michelle Keefe remains on Company Board and member of its executive leadership team.
Interim results for the six months ended 30 June 2023
29 sept. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...